[August 09, 2017] |
|
Innovus Pharma Orders its First Commercial Batch of 220,000 Units of FlutiCare™
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter medicine
and consumer care products to improve men's and women's health and
respiratory diseases, today announced that it ordered 220,000 units of
its FlutiCare™ drug destined for its projected launch in Q4 2017 in the
U.S. The Company is on target with its planned launch in the fourth
quarter of 2017 of its FlutiCare™ product, the third national branded
OTC fluticasone propionate nasal spray in the allergic rhinitis market.
Innovus Pharma will launch the 120 spray version of the drug which it
believes has the highest potential profit margin for the Company.
The Company ordered one batch of the drug from its partner West-Ward for
Q4 2017 and has committed multiple batches for 2018 and 2019 and
currently expects to receive over $3.0 million in gross revenues for
each batch it sells in the U.S. market.
As part of those commercialization efforts, the Company has or is
completing the following tasks:
-
Receiving the first commercial batch of 220,000 units is expected to
be delivered in September/October 2017;
-
Finalizing agreements with wholesalers, retail stores in which we are
a vendor of record and independent pharmacies;
-
Preparing to provide sampling to the top 20% prescribers of
fluticasone propionate nasal spray;
-
Creating direct sampling and coupon programs to consumers to continue
to build brand awareness;
-
Preparing to launch under its Beyond Human® sales and marketing
platform through print and online media; and
-
Preparing to launch through its online platforms including our
website, its over 2 million email subscriber lists and Amazon® stores.
"We are very excited about the upcoming commercial launch of our
FlutiCare™ product in the United States," said Dr. Bassam Damaj, the
President and Chief Executive Officer of Innovus Pharma. "We have
ordered our initial commercial batch of the product, are finalizing our
on-line, Beyond Human®, retail and wholesale sales and marketing efforts
and are gearing up for a successful launch of FlutiCare™ in the fourth
quarter of this year. We believe that the launch of FlutiCare™ should
have an important impact on the gross revenues of the Company in the
future for 2017 and beyond."
About FlutiCare™
FlutiCare™ is the Company's nationally branded OvertheCounter
("OTC") fluticasone propionate nasal spray, USP 50 mcg per spray, which
is indicated to treat individuals with allergic rhinitis, or more
commonly referred to as "allergies". Allergic rhinitis is one of the
most common ailments in the western world and is continuing to grow as
there are approximately 50 million sufferers in the U.S. alone according
to GlobalData.
FlutiCare™ is the first and only nationally branded OTC product under
approved ANDA No. 207957 in the U.S. market. FlutiCare™, which is
equivalent to Flonase® by GlaxoSmithKline and ClariSpray® by Bayer, is
the third national brand being marketed and sold in the U.S. Innovus
Pharma will be launching the 120-spray version through its various
marketing and sales channels.
The trademark Flonase® is a registered trademark wned by
GlaxoSmithKline and the trademark ClariSpray® is a registered trademark
owned by Bayer®.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men's
and women's health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application ("ANDA") products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC.
For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
www.pevarx.com
and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from its FlutiCare™ product and other products in
the United States and abroad estimated market for its products, and
statements about achieving its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company's most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC (News - Alert). Copies of these reports
are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170809005425/en/
[ Back To Homepage ]
|